7 results about "Disease irritable bowel" patented technology

The invention provides a chemical entity of Formula (I):wherein R1, R2, X, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods as disclosed herein, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.

This invention discloses a method for preparing an oral nanoparticle formulation of apigenin, belonging to the field of traditional Chinese medicine preparation technology. The method uses a mixture of soybean protein and xylan as the aqueous phase and an apigenin ethanol solution as the organic phase. Nanoparticles are prepared by antisolvent precipitation, followed by adsorption of tannic acid to obtain the final product. The nanoparticles prepared by this invention have a particle size of less than 600 nm and a high encapsulation efficiency. Utilizing the synergistic effect of soybean protein, xylan, and tannic acid, apigenin is protected from gastric acid degradation, achieving targeted intestinal delivery and significantly improving its oral bioavailability. This method can be used to prepare drugs for treating intestinal diseases such as inflammatory bowel disease, irritable bowel syndrome, or colorectal cancer.

This document relates to methods and materials involved in treating a mammal having a gastrointestinal disorder (e.g., an irritable bowel syndrome (IBS) such as post-infection IBS (PI-IBS)). For example, one or more protease inhibitors and / or one or more microorganisms that produce one or more protease inhibitors can be administered to a mammal having, or at risk of developing, a gastrointestinal disorder to treat the mammal.

Provided herein is a bulk composition comprising the trihydrate form of (3S, 4R, 3′R)-6-[4-(4-amino-5-chloro-2-methoxy-benzoylamino)-3-methoxy-piperidin-1-yl]-hexanoic acid 1-azabicyclo[2.2.2]oct-3′-yl ester di-hydrochloride salt. Provided are also pharmaceutical compositions and dosage forms comprising the trihydrate form, and methods and uses for treating a gastrointestinal disorder in a subject with the trihydrate form. In some embodiments, the gastrointestinal disorder is gastroesophageal reflux disease (GERD), dyspepsia (such as functional dyspepsia or functional motility disorder), gastroparesis, paralytic ileus, post-operative ileus, emesis, nausea, heartburn, intestinal pseudo-obstruction, irritable bowel syndrome (IBS), constipation, enteral feeding intolerance (EFI), or esophagitis. In some embodiments, the gastrointestinal disorder is post-operative ileus, chronic grass sickness, constipation, megacolon, gastritis, gastrointestinal stasis, or abomasal emptying defect.

Described herein are compositions and methods of treating gastrointestinal diseases and disorders such as irritable bowel syndrome and small intestinal bacterial overgrowth.

The present invention relates to a microbiome-based sitz bath method for patients with bowel disease. By periodically performing sitz baths for a certain period of time on mice induced with inflammatory bowel disease using sitz bath water containing an industrial lactic acid bacteria product as a microbial agent, it was confirmed that not only were symptoms of inflammatory bowel disease alleviated, but also the level of inflammatory cytokines was significantly reduced, compared to mouse groups orally or rectally administered with the lactic acid bacteria product. Accordingly, the present invention demonstrates that inflammatory bowel disease in the actual intestine is alleviated when a microbial agent such as a lactic acid bacteria product is included in sitz bath water for sitz bathing, and is thus provided as a microbiome-based sitz bath method for patients with bowel disease.

A chemical entity of Formula (I):wherein V, W, Y, and Z, have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, cognitive disorders, neurodegenerative diseases, and trauma-dependent losses of function; enhancing the efficiency of cognitive and motor training, including in stroke or TBI rehabilitation; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, dermatological, inflammatory, and pain disorders.